Adult acetaminophen has seen a significant decline in sales in 2021. This is explained by the fact that during the start of COVID-19 pandemic in 2020 consumers began to stockpile significant supplies of acetaminophen with the category recording double-digit growth.
Adult combination products – analgesics and naproxen are seeing the most dynamic growth rates in current value terms in 2021. These categories are benefiting from strong investments being made in advertising and promotion by the leading players.
OTCPharm has continued to cement its leading position in analgesics in 2021, largely through the offer of a wide portfolio of brands, supported by promotional and advertising investments. This performance is underpinned by Pentalgin and Next, the company’s largest brands, which are both set to see a further increase in their respective value shares in 2021.
Limited purchasing power, compounded by rising unemployment due to the COVID-19 pandemic, is expected to limit the growth of analgesics. With incomes stretched the main focus will likely be on a product’s efficacy, with this taking precedence over other claims, such as natural ingredients.
Aspirin will remain a key product in analgesics and should see an improved performance over the forecast period, with sales having suffered a setback in 2021 due to consumers stockpiling aspirin in 2020. Aspirin products positioned as anticoagulant and antithrombotic agents (eg Cardiomagnyl, Trombo ACC) should continue to be particularly successful.
Adult naproxen has the potential for strong growth over the forecast period with growth coming from a low base. These products are being widely promoted and advertised, with players seeing potential in the fact they are not included in the government’s price regulation.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Understand the latest market trends and future growth opportunities for the Analgesics industry in Russia with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Analgesics industry in Russia, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
Analgesics cover systemic and topical pain relievers. Products which include a pain-relief ingredient in addition to another core function are excluded (e.g. a sore throat remedy which includes paracetamol is excluded from the analgesics and instead is included in pharyngeal remedies).See All of Our Definitions
This report originates from Passport, our Analgesics research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!